Abstract
The prevalence of disease-related BRCA1 mutations was investigated in 642 Dutch breast cancer patients not selected for family history or age at diagnosis. They were tested for germline mutations in the BRCA1 gene using an assay which detects small deletions and insertions (DSDI), as well as the two major genomic founder deletions present in the Dutch population. Data on family history and bilateral breast cancer were obtained retrospectively. Ten protein truncating mutations were detected and one in-frame deletion with an unknown relation to disease risk. Four patients carried the Dutch founder deletion of exon 22. Based on these results the estimated prevalence of breast cancer in the general population in the Netherlands attributable to BRCA1 mutations is 2.1%. Under 40 years-of-age and under 50 years-of-age this prevalence is 9.5% and 6.4%, respectively. All mutation carriers were under 50 years-of-age at diagnosis of the first breast cancer, and five did not have any relative with breast cancer. The proportions of bilateral breast cancer in the mutation carriers and non-carriers did not differ from each other. These data indicate that in the general Dutch breast cancer population the great majority of BRCA1 mutations will be found in women diagnosed under 50 years-of-age. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N and Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60: 505–514
Coebergh JW, van der Heijden LH and Janssen-Heijnen ML (1995) Cancer incidence and survival. Comprehensive Cancer Center South, 54–55
Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T and Weber BL (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336: 1409–1415
Devilee P (1999) BRCA1 and BRCA2 testing: Weighting the demand against the benefits. Am J Hum Genet 64: 943–948
Easton DF, Ford D and Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265–271
FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O’Neil E, Unsal H, Silva AS, Finkelstein DM, Beer RP, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH and Haber DA (1996) Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 334: 143–149
Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST and Eng CM (1998) Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 63: 45–51
Ford D, Easton DF and Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57: 1457–1462
Hartge P, Struewing J, Wacholder S, Brody LC and Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64: 963–970
Hogervorst F, Cornelis RS, Bout M, van Vliet M, Oosterwijk JC, Olmer R and Bakker B (1995) Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 10: 208–212
Langston AA, Malone KE, Thompson JD, Daling JR and Ostrander EA (1996) BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 334: 137–142
Ligtenberg MJ, Hogervorst FB, Willems HW, Arts PJ, Brink G, Hageman S, Bosgoed EA, Van-der-Looij E, Rookus MA, Devilee P, Vos EM, Wigbout G, Struycken PM, Menko FH, Rutgers EJ, Hoefsloot EH, Mariman EC, Brunner HG and van’t- Veer LJ (1999) Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. Br J Cancer 79: 1475–1478
Malone KE, Daling JR, Thompson JD, O’Brien CA, Francisco LV and Ostrander EA (1998) BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279: 922–929
Martin JG and Altman GA (1989). Statistics with confidence – confidence intervals and statistical guidelines. British Medical Journal Publications: London
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barret JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A and Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71
Millar SA, Dykes DD and Polesky HF (1998) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215
Newman B, Mu H, Butler LM, Millikan RC, Moorman PG and King MC (1998) Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279: 915–921
Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van-den-Ouweland AM, Hogervorst F, Brohet R, Ligtenberg MJ, Teugels E, van-der-Luijt R, van-der-Hout AH, Gille JJ, Pals G, Jedema I, Olmer R, van LI, Newman B, Plandsoen M, van-der-Est M, Brink G, Hageman S, Arts PJ, Bakker MM and Devilee P (1997) A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 60: 1041–1049
Petrij-Bosch A, Peelen T, van-Vliet M, van-Eijk R, Olmer R, Drusedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers HH, Klijn JG, Vasen HF, Cornelisse CJ, van’t-Veer LJ, Bakker E, van-Ommen GJ and Devilee P (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17: 341–345
Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N, Staebell M, Gumpper K, Lundstrom R, Hulick M, Kelly M, Holmen J, Lingenfelter B, Manley S, Fujimura F, Luce M, Ward B, Cannon AL, Steele L, Offit K and Thomas A (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278: 1242–1250
Shuber AP, Grondin VJ and Klinger KW (1995) A simplified procedure for developing multiplex PCRs. Genome Res 5: 488–493
Southey MC, Tesoriero A, Andersen CR, Jennings KM, Brown SM, Dite G, Jenkins MA, Osborne RH, Maskiell JA, Porter L, Giles GG, McCredie MR, Hopper JL and Venter DJ (1999) BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br J Cancer 79: 34–39
Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC and Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401–1408
Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner CJ, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Lynch HT, Lenoir GM, Narod SA and Garber JE (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2: 1179–1183
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C and Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789–792
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Papelard, H., de Bock, G., van Eijk, R. et al. Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br J Cancer 83, 719–724 (2000). https://doi.org/10.1054/bjoc.2000.1331
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1331
Keywords
This article is cited by
-
Cancer treatment according to BRCA1 and BRCA2 mutations
Nature Reviews Clinical Oncology (2012)
-
On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations
European Journal of Human Genetics (2011)
-
Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases
British Journal of Cancer (2009)
-
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations
Nature Reviews Cancer (2007)
-
The correlation of mammographic-and histologic patterns of breast cancers in BRCA1 gene mutation carriers, compared to age-matched sporadic controls
European Radiology (2006)